Beyond Air, Inc. announced the appointments of Rebecca Van Doren as Head of Sales and Kori-Ann Taylor as Head of Marketing. Rebecca Van Doren brings over 20 years of healthcare leadership and sales experience to Beyond Air, dedicating the majority of her career to envisioning and invigorating winning commercial strategies for nitric oxide, both in the US and Australia with Ikaria and Mallinckrodt Pharmaceuticals. As Head of Sales at Beyond Air, Ms. Van Doren will lead all sales operations for the US. Kori-Ann Taylor joins Beyond Air as an experienced marketing leader within the healthcare industry. She has a strong track record of success in developing winning strategies, building results-driven teams, and driving integrated marketing campaigns in rapidly changing competitive landscapes across various device and pharmaceutical brands. Ms. Taylor joins Beyond Air from aptihealth, where she served as the Chief Marketing Officer, responsible for brand building, developing, and leading all marketing initiatives and launches across health plans and hospital systems. Before her time at aptihealth, Ms. Taylor spent over a decade as an award-winning account lead at highly respected marketing agencies, including Fingerpaint Marketing and Palio, leading U.S. and global campaign development and launches for healthcare brands. As Head of Marketing at Beyond Air, Ms. Taylor will drive the development and execution of comprehensive marketing strategies across all products and launches. She also will oversee corporate and product brand building for Beyond Air's extensive pipeline, positioning Beyond Air for tremendous growth.
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Companyâs LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Companyâs areas of focus with LungFit are persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology that generates on-demand NO from ambient air and, regardless of dose or flow, delivers it to a ventilator circuit. The LungFit can generate up to 400 parts per million (ppm) of NO.
BEYOND AIR, INC. 
